Board of
Directors
Dr Chris Nave
Chairperson and director
Chris is a founding partner and Managing Director of Brandon Capital and Chief Executive Officer of Brandon BioCatalyst. Chris has more than 20 years of experience in venture capital investing into pharmaceutical and medical device companies. Previous roles both locally and internationally in the pharmaceutical, technology transfer and biotechnology industries have seen Chris involved directly in the management, fundraising and growth of biomedical companies.
Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.
Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry. In October 2014, Chris was awarded the AusBiotech Johnson & Johnson Industry Leadership Award.
Chris is currently a Director of OccuRx Pty Ltd, Osprey Medical Inc., PolyActiva Pty Ltd, Global Kinetics Corporation, QueOncology Pty Ltd, Azura Ophthalmics, EBR Systems Inc, Pathios Therapeutics Ltd., and Cardiora Pty Ltd. Chris was also Chairperson of Fibrotech Therapeutics at the time of its successful sale to Shire and a Director of Spinifex Pharmaceuticals at the time of its sale to Novartis.
Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.
Mr Tom Mathers
Vice Chair and Director
Tom Mathers joined Certa Therapeutics as Vice Chairman in 2025.
Tom is a partner at Pappas Capital and has more than 30 years of executive management experience in the life science and medical device industries. He operates out of Boston and focuses primarily on company formation. Tom currently serves as the Executive Chairman of the Board for Aer Therapeutics, Inc., a Pappas Ventures VI portfolio company. He also serves as Treasurer and a member of the Executive Committee of the Board of Directors for the Biotechnology Innovation Organization (BIO), where he is active in the areas of advocacy, regulatory policy, capital formation, bioethics and intellectual property policy.
In 2019, Tom founded Allievex Corp., a Pappas Ventures V portfolio company, and served as its President and CEO, as well as a director, until its acquisition in 2024. Prior to Allievex, He was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Pappas Ventures III founded company, which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid in 2017 in an all-cash transaction worth nearly $1 billion. Prior to CoLucid, Tom was President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc.; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme Corporation.
Tom is also a Member of the Department of Veteran’s Affairs Research Advisory Committee on Gulf War Veterans’ Illnesses (RACGWVI). From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War.
Darren has published over 200 manuscripts in the field of translational research and novel interventions, many of which have had a direct impact on human disease. In 2009, Darren was a recipient of the prestigious TJ Neale award for outstanding contribution to nephrology. In 2015 Darren joined the Medical Research Commercialisation Fund as Venture Partner.
Darren has a proven history in translational research. He was previously Founder, CEO and Director of Fibrotech Therapeutics, a company that developed orally active anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure, which was ultimately acquired by Shire Plc for a record 75 million USD upfront including milestone payments up to 600 million USD.
Darren has a PhD in Translational Medicine from the University of Melbourne, and an Executive Diploma Business Administration. He is a current member of the Australian Institute of Company Directors and a Fellow of the American Society of Nephrology.
Dr John Kurek
DIRECTOR
John has 20 years of industry experience as a Biotechnology Manager with a focus on the strategic design and implementation of drug development programs. John is the Biotechnology Investment Manager of Uniseed, a $70m venture fund, operating at the Universities of Melbourne, Queensland, Sydney, New South Wales and the CSIRO.
In this role, John is responsible for identifying new investment opportunities and managing Uniseed’s overall biotechnology and life sciences portfolio.
John’s previous roles have included Pharmaceutical Development Manager at BioDiem Ltd., managing the preclinical, clinical and regulatory aspects of BioDiem’s drug development programs, and Preclinical Development Manager at Amrad Corporation Ltd., where he was responsible for the management of preclinical drug development projects. His experience extends from drug discovery to the clinical phase of drug development.
John has a PhD in neuroscience and a Post Graduate Diploma in drug evaluation and pharmaceutical science, both from the University of Melbourne, and is a graduate of the Australian Institute of Company Directors.
Professor Carol Pollock
INDEPENDENT DIRECTOR
Professor Carol Pollock is an academic nephrologist with over 310 publications in basic research, largely relating to renal fibrosis and progressive renal disease as well as in clinical trials.
Carol is an inaugural Fellow of the Australian Academy of Health and Medical Sciences (2015), was conferred a Vice Chancellors Award for Excellence in Research Supervision (2012) and recognised as a ‘Distinguished Professor’ by the University of Sydney (2012).
Carol was the 2014 recipient of the Ministerial Award for Excellence in Cardiovascular Research and was Scientific Chairman of the 2013 World Congress of Nephrology. Carol is Chair of Kidney Health Australia, Deputy Chair of the Board of the Australian Organ, Tissue and Transplant Authority; Chair of the NSW Cardiovascular Research Network and inaugural Chair and now co-chair of the Research Advisory Committee of the Australian and New Zealand Society of Nephrology. Carol’s health leadership roles also include inaugural Chair of the NSW Agency for Clinical Innovation, immediate past Chair of the Clinical Excellence Commission, remaining as a director of both organisations till April 2016. Carol was Chair of the Northern Sydney Local Health District Board since its inception in 2011 till Dec 2016, was appointed to the Board of the Bureau of Health Information in April 2016 and assumed Chairmanship of the Bureau in November 2016. Carol is the current Convenor of the NSW Council of Board Chairs of Local Health Districts and Specialty Networks.